Madrigal Pharmaceuticals Stock Today
| MDGL Stock | USD 309.49 12.65 3.93% |
PerformanceVery Weak
| Odds Of DistressLow
|
Madrigal Pharmaceuticals is selling for 309.49 as of the 25th of February 2025. This is a 3.93 percent decrease since the beginning of the trading day. The stock's lowest day price was 309.36. Madrigal Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of February 2007 | Category Healthcare | Classification Health Care |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. The company has 21.81 M outstanding shares of which 3.98 M shares are now shorted by private and institutional investors with about 8.8 trading days to cover. More on Madrigal Pharmaceuticals
Moving against Madrigal Stock
Madrigal Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | William Sibold | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMadrigal Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Madrigal Pharmaceuticals' financial leverage. It provides some insight into what part of Madrigal Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Madrigal Pharmaceuticals (MDGL) is traded on NASDAQ Exchange in USA. It is located in Four Tower Bridge, West Conshohocken, PA, United States, 19428 and employs 376 people. Madrigal Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.03 B. Madrigal Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 21.81 M outstanding shares of which 3.98 M shares are now shorted by private and institutional investors with about 8.8 trading days to cover.
Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Check Madrigal Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Madrigal Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Madrigal Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Madrigal Pharmaceuticals. Please pay attention to any change in the institutional holdings of Madrigal Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Madrigal Ownership Details
Madrigal Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| William Blair Investment Management, Llc | 2024-12-31 | 371.8 K | |
| Ubs Group Ag | 2024-12-31 | 325.3 K | |
| Woodline Partners Lp | 2024-12-31 | 309.1 K | |
| Rock Springs Capital Management Lp | 2024-12-31 | 265.2 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 231.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 218.5 K | |
| Bank Of America Corp | 2024-12-31 | 217.8 K | |
| Artisan Partners Limited Partnership | 2024-12-31 | 207.5 K | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 199.7 K | |
| Hhg Plc | 2024-12-31 | 2.2 M | |
| Paulson & Company Inc | 2024-12-31 | 2 M |
Madrigal Pharmaceuticals Historical Income Statement
Madrigal Stock Against Markets
Madrigal Pharmaceuticals Corporate Management
| Justin Drinkwine | Senior VP | Profile | |
| Thomas Hare | Senior Management | Profile | |
| Remy Sukhija | VP Officer | Profile | |
| PharmD MBA | Senior Affairs | Profile | |
| Mark Underwood | Senior Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.